Dystonia - Pipeline Review, H2 2012

Global Markets Direct, September 2012, Pages: 47

Dystonia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Dystonia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Dystonia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dystonia. Dystonia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Dystonia.
- A review of the Dystonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Dystonia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Dystonia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Dystonia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Dystonia Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Dystonia 7
Dystonia Therapeutics under Development by Companies 9
Dystonia Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Dystonia Therapeutics – Products under Development by Companies 14
Dystonia Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Dystonia Therapeutics Development 16
Johnson & Johnson 16
Ipsen S.A. 17
Addex Pharmaceuticals 18
Alnylam Pharmaceuticals, Inc 19
EpiVax, Inc. 20
QRxPharma Limited 21
Dystonia – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
ADX-48621 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Drug For Dystonia - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
onabotulinumtoxinA - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Amlodipine + Botulinum toxin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
T-9001 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
onaclostox - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Dystonia Therapeutics – Drug Profile Updates 35
Dystonia Therapeutics – Discontinued Products 37
Dystonia Therapeutics - Dormant Products 38
Dystonia – Product Development Milestones 39
Featured News & Press Releases 39
Apr 23, 2012: Merz To Present Phase IV XEOMIN Data At 64th AAN Annual Meeting 39
Mar 15, 2012: US Court Restricts Sale Of Merz's Xeomin And Dermal Fillers In US 40
Jan 04, 2012: Merz Pharmaceuticals Receives J-Code For Xeomin From Centers For Medicare And Medicaid Services 40
Nov 17, 2011: Merz To Present XEOMIN Data At 72nd Annual Assembly Of American Academy Of Physical Medicine And Rehabilitation 41
Oct 21, 2011: Merz Research Shows Long-term Benefits For Patients With Dystonia 42
Apr 12, 2011: Merz's XEOMIN Data To Be Presented At 63rd Annual Meeting Of American Academy Of Neurology 43
Mar 30, 2011: CMS Grants New HCPCS Billing Code For Xeomin 43
Nov 05, 2010: Merz To Present Data On Xeomin At 71st Annual Assembly Of American Academy Of Physical Medicine And Rehabilitation 44
Sep 20, 2010: Merz Pharma Launches XEOMIN Patient Assistance Plan In Canada 45
Sep 07, 2010: MERZ Pharma's XEOMIN Listed With Regular Benefit Status On AHWDBL 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables
Number of Products Under Development for Dystonia, H2 2012 7
Products under Development for Dystonia – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Johnson & Johnson, H2 2012 16
Ipsen S.A., H2 2012 17
Addex Pharmaceuticals, H2 2012 18
Alnylam Pharmaceuticals, Inc, H2 2012 19
EpiVax, Inc., H2 2012 20
QRxPharma Limited, H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 27
Dystonia Therapeutics – Drug Profile Updates 35
Dystonia Therapeutics – Discontinued Products 37
Dystonia Therapeutics – Dormant Products 38

List of Figures
Number of Products under Development for Dystonia, H2 2012 7
Products under Development for Dystonia – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Route of Administration, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Molecule Type, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 27

Customers who bought this item also bought

• Dystonia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
• Handbook of Dystonia. Edition No. 2. Neurological Disease and Therapy
• RNA Interference (RNAi) - Global Strategic Business Report
• Global Biopharmaceutical Market Report & Forecast (2012-2017)
• World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast
• Nuclear Medicine - Global Strategic Business Report
• Pediatric Drugs and Vaccines - Global Business Strategic Report
• IV Fluid Transfer Devices Products, Players, Markets and Opportunities
• Therapeutic Apheresis - A US Market Report
• Regenerative Medicine - Global Strategic Business Report